Drug Information Services: Services providing pharmaceutic and therapeutic drug information and consultation.Pamphlets: Printed publications usually having a format with no binding and no cover and having fewer than some set number of pages. They are often devoted to a single subject.Drug Labeling: Use of written, printed, or graphic materials upon or accompanying a drug container or wrapper. It includes contents, indications, effects, dosages, routes, methods, frequency and duration of administration, warnings, hazards, contraindications, side effects, precautions, and other relevant information.Patient Education as Topic: The teaching or training of patients concerning their own health needs.Formularies as Topic: Works about lists of drugs or collections of recipes, formulas, and prescriptions for the compounding of medicinal preparations. Formularies differ from PHARMACOPOEIAS in that they are less complete, lacking full descriptions of the drugs, their formulations, analytic composition, chemical properties, etc. In hospitals, formularies list all drugs commonly stocked in the hospital pharmacy.Drug Industry: That segment of commercial enterprise devoted to the design, development, and manufacture of chemical products for use in the diagnosis and treatment of disease, disability, or other dysfunction, or to improve function.Medical Records Systems, Computerized: Computer-based systems for input, storage, display, retrieval, and printing of information contained in a patient's medical record.Advertising as Topic: The act or practice of calling public attention to a product, service, need, etc., especially by paid announcements in newspapers, magazines, on radio, or on television. (Random House Unabridged Dictionary, 2d ed)Computer Security: Protective measures against unauthorized access to or interference with computer operating systems, telecommunications, or data structures, especially the modification, deletion, destruction, or release of data in computers. It includes methods of forestalling interference by computer viruses or so-called computer hackers aiming to compromise stored data.Therapeutic Equivalency: The relative equivalency in the efficacy of different modes of treatment of a disease, most often used to compare the efficacy of different pharmaceuticals to treat a given disease.alpha-Macroglobulins: Glycoproteins with a molecular weight of approximately 620,000 to 680,000. Precipitation by electrophoresis is in the alpha region. They include alpha 1-macroglobulins and alpha 2-macroglobulins. These proteins exhibit trypsin-, chymotrypsin-, thrombin-, and plasmin-binding activity and function as hormonal transporters.Patents as Topic: Exclusive legal rights or privileges applied to inventions, plants, etc.Inventions: A novel composition, device, or process, independently conceived de novo or derived from a pre-existing model.Intellectual Property: Property, such as patents, trademarks, and copyright, that results from creative effort. The Patent and Copyright Clause (Art. 1, Sec. 8, cl. 8) of the United States Constitution provides for promoting the progress of science and useful arts by securing for limited times to authors and inventors, the exclusive right to their respective writings and discoveries. (From Black's Law Dictionary, 5th ed, p1014)History, 18th Century: Time period from 1701 through 1800 of the common era.Biotechnology: Body of knowledge related to the use of organisms, cells or cell-derived constituents for the purpose of developing products which are technically, scientifically and clinically useful. Alteration of biologic function at the molecular level (i.e., GENETIC ENGINEERING) is a central focus; laboratory methods used include TRANSFECTION and CLONING technologies, sequence and structure analysis algorithms, computer databases, and gene and protein structure function analysis and prediction.History, 17th Century: Time period from 1601 through 1700 of the common era.History, 20th Century: Time period from 1901 through 2000 of the common era.History, 19th Century: Time period from 1801 through 1900 of the common era.Body Composition: The relative amounts of various components in the body, such as percentage of body fat.Administration, Oral: The giving of drugs, chemicals, or other substances by mouth.Food Coloring Agents: Natural or synthetic dyes used as coloring agents in processed foods.Nonprescription Drugs: Medicines that can be sold legally without a DRUG PRESCRIPTION.Student Health Services: Health services for college and university students usually provided by the educational institution.Preservatives, Pharmaceutical: Substances added to pharmaceutical preparations to protect them from chemical change or microbial action. They include ANTI-BACTERIAL AGENTS and antioxidants.Food Preservatives: Substances capable of inhibiting, retarding or arresting the process of fermentation, acidification or other deterioration of foods.Pharmacopoeias as Topic: Authoritative treatises on drugs and preparations, their description, formulation, analytic composition, physical constants, main chemical properties used in identification, standards for strength, purity, and dosage, chemical tests for determining identity and purity, etc. They are usually published under governmental jurisdiction (e.g., USP, the United States Pharmacopoeia; BP, British Pharmacopoeia; P. Helv., the Swiss Pharmacopoeia). They differ from FORMULARIES in that they are far more complete: formularies tend to be mere listings of formulas and prescriptions.Age Factors: Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time.Tartrazine: An anionic, hydrophilic azo dye with an orange-yellow color used in fabrics, foods and cosmetics, and as a biological stain.LouisianaAbsorbable Implants: Implants constructed of materials designed to be absorbed by the body without producing an immune response. They are usually composed of plastics and are frequently used in orthopedics and orthodontics.Alloys: A mixture of metallic elements or compounds with other metallic or metalloid elements in varying proportions.Anti-Inflammatory Agents, Non-Steroidal: Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions.They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.Prostheses and Implants: Artificial substitutes for body parts, and materials inserted into tissue for functional, cosmetic, or therapeutic purposes. Prostheses can be functional, as in the case of artificial arms and legs, or cosmetic, as in the case of an artificial eye. Implants, all surgically inserted or grafted into the body, tend to be used therapeutically. IMPLANTS, EXPERIMENTAL is available for those used experimentally.Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.Sinusitis: Inflammation of the NASAL MUCOSA in one or more of the PARANASAL SINUSES.Mucociliary Clearance: A non-specific host defense mechanism that removes MUCUS and other material from the LUNGS by ciliary and secretory activity of the tracheobronchial submucosal glands. It is measured in vivo as mucus transfer, ciliary beat frequency, and clearance of radioactive tracers.Maxillary Sinus: The air space located in the body of the MAXILLARY BONE near each cheek. Each maxillary sinus communicates with the middle passage (meatus) of the NASAL CAVITY on the same side.Maxillary Sinusitis: Inflammation of the NASAL MUCOSA in the MAXILLARY SINUS. In many cases, it is caused by an infection of the bacteria HAEMOPHILUS INFLUENZAE; STREPTOCOCCUS PNEUMONIAE; or STAPHYLOCOCCUS AUREUS.Viscosity: The resistance that a gaseous or liquid system offers to flow when it is subjected to shear stress. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed)Foramen Ovale, Patent: A condition in which the FORAMEN OVALE in the ATRIAL SEPTUM fails to close shortly after birth. This results in abnormal communications between the two upper chambers of the heart. An isolated patent ovale foramen without other structural heart defects is usually of no hemodynamic significance.Sphenoid Sinusitis: Inflammation of the NASAL MUCOSA in the SPHENOID SINUS. Isolated sphenoid sinusitis is uncommon. It usually occurs in conjunction with other paranasal sinusitis.Dictionaries, MedicalAmoeba: A genus of ameboid protozoa. Characteristics include a vesicular nucleus and the formation of several lodopodia, one of which is dominant at a given time. Reproduction occurs asexually by binary fission.Dictionaries as Topic: Lists of words, usually in alphabetical order, giving information about form, pronunciation, etymology, grammar, and meaning.Dictionaries, ChemicalTerminology as Topic: The terms, expressions, designations, or symbols used in a particular science, discipline, or specialized subject area.Amebiasis: Infection with any of various amebae. It is an asymptomatic carrier state in most individuals, but diseases ranging from chronic, mild diarrhea to fulminant dysentery may occur.Peptide Library: A collection of cloned peptides, or chemically synthesized peptides, frequently consisting of all possible combinations of amino acids making up an n-amino acid peptide.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.Amino Acid Sequence: The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.Immunoglobulin Heavy Chains: The largest of polypeptide chains comprising immunoglobulins. They contain 450 to 600 amino acid residues per chain, and have molecular weights of 51-72 kDa.Visual Prosthesis: Artificial device such as an externally-worn camera attached to a stimulator on the RETINA, OPTIC NERVE, or VISUAL CORTEX, intended to restore or amplify vision.Antibody Specificity: The property of antibodies which enables them to react with some ANTIGENIC DETERMINANTS and not with others. Specificity is dependent on chemical composition, physical forces, and molecular structure at the binding site.Molecular Sequence Data: Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.Immunoglobulin Variable Region: That region of the immunoglobulin molecule that varies in its amino acid sequence and composition, and comprises the binding site for a specific antigen. It is located at the N-terminus of the Fab fragment of the immunoglobulin. It includes hypervariable regions (COMPLEMENTARITY DETERMINING REGIONS) and framework regions.Device Approval: Process that is gone through in order for a device to receive approval by a government regulatory agency. This includes any required preclinical or clinical testing, review, submission, and evaluation of the applications and test results, and post-marketing surveillance. It is not restricted to FDA.Gene Expression Profiling: The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.Equipment Design: Methods of creating machines and devices.Myelitis, Transverse: Inflammation of a transverse portion of the spinal cord characterized by acute or subacute segmental demyelination or necrosis. The condition may occur sporadically, follow an infection or vaccination, or present as a paraneoplastic syndrome (see also ENCEPHALOMYELITIS, ACUTE DISSEMINATED). Clinical manifestations include motor weakness, sensory loss, and incontinence. (Adams et al., Principles of Neurology, 6th ed, pp1242-6)Intrauterine Devices: Contraceptive devices placed high in the uterine fundus.Molecular Conformation: The characteristic three-dimensional shape of a molecule.Equipment Safety: Freedom of equipment from actual or potential hazards.Abbreviations as Topic: Shortened forms of written words or phrases used for brevity.DictionaryNatural Language Processing: Computer processing of a language with rules that reflect and describe current usage rather than prescribed usage.Dictionaries, PharmaceuticDictionaries, DentalUnified Medical Language System: A research and development program initiated by the NATIONAL LIBRARY OF MEDICINE to build knowledge sources for the purpose of aiding the development of systems that help health professionals retrieve and integrate biomedical information. The knowledge sources can be used to link disparate information systems to overcome retrieval problems caused by differences in terminology and the scattering of relevant information across many databases. The three knowledge sources are the Metathesaurus, the Semantic Network, and the Specialist Lexicon.

The pharmacokinetics of mecillinam and pivmecillinam in pregnant and non-pregnant women. (1/20)

1. The pharmacokinetics of parenteral mecillinam (n = 27) and oral pivmecillinam (n = 12) were studied in pregnant (n = 27) and non-pregnant (n = 12) subjects. 2. In early pregnancy (9-14 weeks of gestation) the mean peak plasma drug concentration (Cmax = 19 +/- 9 micrograms ml-1) after an intravenous injection of 200 mg mecillinam was significantly lower (P less than 0.05) and the volume of distribution (V = 49 +/- 20.1) significantly larger (P less than 0.05) than in non-pregnant subjects (Cmax = 35 +/- 18 micrograms ml-1, V = 29 +/- 12.1). In late pregnancy (39-40 weeks of gestation) the plasma mean peak concentration (Cmax = (29 +/- 14 micrograms ml-1) after parenteral administration of 200 mg mecillinam was slightly lower and the volume of distribution (V = 65 +/- 29.1, V = 0.9 +/- 0.4 l kg-1) significantly larger than that in non-pregnant subjects (V = 0.4 +/- 0.3 l kg-1). Also after oral administration of 200 mg pivmecillinam, equimolar to 136.5 mg mecillinam, the mean peak plasma concentration in pregnant subjects (Cmax = 1.8 +/- 1.2 micrograms ml-1) was slightly lower than that in non-pregnant subjects (Cmax = 1.7 +/- 1.2 micrograms ml-1). 3. The mean half-life of elimination after parenteral administration of mecillinam was significantly longer during both early (t1/2,Z = 133 +/- 38 min, P less than 0.05) and late pregnancy (t1/2,Z = 107 +/- 41 min, P less than 0.05) as compared with the non-pregnant state (t1/2,Z = 75 +/- 21 min).(ABSTRACT TRUNCATED AT 250 WORDS)  (+info)

Ecological effects of perorally administered pivmecillinam on the normal vaginal microflora. (2/20)

The knowledge of the effects of antimicrobial agents on the normal vaginal microflora is limited. The objective of the present study was to study the ecological impact of pivmecillinam on the normal vaginal microflora. In 20 healthy women, the estimated day of ovulation was determined during three subsequent menstrual cycles. Microbiological and clinical examinations were performed on the estimated day of ovulation and on day 3 in all cycles and also on day 7 after ovulation in cycles 1 and 2. Anaerobic and facultative anaerobic gram-positive rods, mainly species of lactobacilli and actinomycetes, dominated the microflora. One woman was colonized on the third day of administration with a resistant Escherichia coli strain, and Candida albicans was detected in one woman on days 3 and 7 in cycle 2. No other major changes in the normal microflora occurred during the study. Administration of pivmecillinam had a minor ecological impact on the normal vaginal microflora.  (+info)

Microflora changes with norfloxacin and pivmecillinam in women with recurrent urinary tract infection. (3/20)

Similar changes in the periurethral and vaginal microflora were observed in 19 women with recurrent urinary tract infection following treatment with norfloxacin (NOR) or pivmecillinam (PIV). Escherichia coli strains were suppressed by both treatments. Staphylococcus spp. and enterococci colony counts increased following PIV treatment in the periurethral flora but remained stable with NOR.  (+info)

Pulsed-field gel electrophoresis typing of Escherichia coli strains from samples collected before and after pivmecillinam or placebo treatment of uncomplicated community-acquired urinary tract infection in women. (4/20)

The primary infecting Escherichia coli strains from 156 women with community-acquired uncomplicated urinary tract infection (UTI) randomized to pivmecillinam or placebo and the E. coli strains causing UTI at two follow-up visits were typed using pulsed-field gel electrophoresis (PFGE). In the pivmecillinam treatment group PFGE showed that among patients having a negative urine culture at the first follow-up 77% (46/60) had a relapse with the primary infecting E. coli strain and 23% (14/60) had reinfection with a new E. coli strain at the second follow-up. Among patients having E. coli at the first follow-up PFGE showed that 80% (32/40) had persistence with the primary infecting E. coli strain, 15% (6/40) had reinfection with a new E. coli strain, and 5% (2/40) had different E. coli strains at the two follow-up visits (one had reinfection followed by relapse, and the other had persistence followed by reinfection). In the placebo group the majority had E. coli at the first follow-up. PFGE showed that among these patients 96% (50/52) had persistence with the primary infecting E. coli strain and 4% (2/50) had different E. coli strains at the two follow-up visits (both had persistence followed by reinfection). The finding that the majority of UTIs at follow-up are caused by the primary infecting E. coli strain supports the theory of a vaginal and rectal reservoir but could also support the recent discovery that E. coli strains are able to persist in the bladder epithelium despite appropriate antibiotic treatment, constituting a reservoir for recurrent UTI.  (+info)

Clinical and bacteriological outcome of different doses and duration of pivmecillinam compared with placebo therapy of uncomplicated lower urinary tract infection in women: the LUTIW project. (5/20)

OBJECTIVE: To analyse associations between symptoms and bacteriuria in uncomplicated lower urinary tract infection in women (LUTIW) and to evaluate outcome of therapy with three different regimens of pivmecillinam or placebo. DESIGN: Prospective, multicentre, randomized, double-blind, and placebo-controlled therapy study. Symptoms registered at inclusion, during therapy and at follow-up visits after 8-10 and 35-49 days. Significant bacteriuria defined according to current European guidelines. SETTING: A total of 18 primary healthcare centres in northern Sweden. Subjects. Women aged 18 years and above with symptoms of urgency, dysuria, supra pubic or loin pain. Main outcome measures. Symptoms and bacteriuria at inclusion and course of symptoms, bacteriuria, and their combinations during and post-therapy. RESULTS: At inclusion, no associations or significant differences were found between symptom scores and bacteriuria, bacterial counts, or species. The 884 patients (77%) with significant bacteriuria were followed up. All pivmecillinam therapies were superior to placebo (p < 0.001). From day six until first follow-up, the mean values of all symptoms were higher and the bacteriological cure was lower at first follow-up in the three days (84%) compared with the seven days regimens (93-94%, p < 0.001). At final follow-up clinical cure was similar in all pivmecillinam regimens (65-72%) as was bacteriological cure (83-89%). Pivmecillinam had few low to mild adverse reactions, comparable to placebo. CONCLUSIONS: Symptoms are not conclusive for diagnosis of LUTIW. Pivmecillinam therapies are superior to placebo and seven days regimens are more efficient than three days. Pivmecillinam 200 mg x 2 x 7 days is recommended as a first-line therapy for LUTIW.  (+info)

Urine bactericidal activity against Escherichia coli isolates exhibiting different resistance phenotypes/genotypes in an in vitro pharmacodynamic model simulating urine concentrations obtained after oral administration of a 400-milligram single dose of cefditoren-pivoxil. (6/20)

Activity of simulated cefditoren urinary concentrations was determined against seven Escherichia coli isolates. Bactericidal activity was obtained from 4 to 24 h against TEM-1 (penicillinase production/hyperproduction), TEM-34 (IRT-6), and TEM-116 (extended-spectrum beta-lactamase [ESBL]) and from 6 to 8 h against SHV/TEM-116 (ESBL) but never against SHV/TEM-1 (ESBL). Extension of bactericidal activity depended on the resistance genotype/phenotype tested.  (+info)

Pivmecillinam versus sulfamethizole for short-term treatment of uncomplicated acute cystitis in general practice: a randomized controlled trial. (7/20)

 (+info)

Association between antimicrobial consumption and resistance in Escherichia coli. (8/20)

 (+info)

*Pivmecillinam

... (INN) or amdinocillin pivoxil (USAN, trade names Selexid, Penomax and Coactabs) is an orally active prodrug of ... Prodrugs that release pivalic acid when broken down by the body - such as pivmecillinam, pivampicillin and cefditoren pivoxil ... Pham P, Bartlett JG (August 28, 2008). "Amdinocillin (Mecillinam)". Point-of-Care Information Technology ABX Guide. Johns ...

*List of MeSH codes (D03)

... amdinocillin MeSH D03.438.260.825.124.036 --- amdinocillin pivoxil MeSH D03.438.260.825.249 --- cyclacillin MeSH D03.438. ... amdinocillin MeSH D03.605.084.737.124.036 --- amdinocillin pivoxil MeSH D03.605.084.737.249 --- cyclacillin MeSH D03.605. ...

*List of MeSH codes (D02)

... amdinocillin MeSH D02.065.589.099.750.124.036 --- amdinocillin pivoxil MeSH D02.065.589.099.750.249 --- cyclacillin MeSH ...
Uncomplicated lower urinary tract infections (LUTIs) are very common (i.e. 10% of all women has it each year and 60% of all women experience at least one episode during their lifetime) [1], and we presume there are about 200,000 patients treated for this in Denmark annually. Most patients are otherwise healthy women, and these infections are often the main reason of exposure to antibiotics for these patients [2]. Uncomplicated LUTIs are primarily community acquired and diagnosed as well as treated in primary care. The most common pathogen is Escherichia coli [2, 3], and diagnosis can be made clinical with 90% positive predictive value (i.e. new onset dysuria, pollakisuria and urgency, together with absence of vaginal discharge or pain) [4].. In Denmark, the current clinical practice recommendations is pivmecillinam (i.e., 400 mg t.i.d for 3 days) as the first line drug against uncomplicated LUTIs [5]. Pivmecillinam is a prodrug of mecillinam. It is an amidinopenicillin, selective and highly ...
The Demon Of Overproduction Real school reforms have always failed, not because they represent bad ideas but because they stand for different interpretations of the purpose of life than the current management of society will allow. If too many people adopted such reforms, a social and economic catastrophe would be provoked, one at least equal to that which followed the original imposition of centralized, collective life on men, women, and children in what had been a fairly libertarian American society. Reverberations of this earlier change in schooling are still being heard. What else do you think the explosion of homeschooling in recent years means? The reason this cataclysm, out of which we got forced schooling, has been put to the question so very little by the groups it violently damaged is that the earlier storm had a confusing aspect to it. Those who suffered most didnt necessarily experience declining incomes. The cost of the metamorphosis was paid for in liberties: loss of freedom, loss ...
BACKGROUND: Fluoroquinolones are extensively used as prophylaxis for transrectal ultrasound-guided biopsy of the prostate (TRUBP). Emerging fluoroquinolone resistance and selection of multiresistant organisms warrant new prophylactic strategies. Pivmecillinam and amoxicillin/clavulanic acid have mutual synergistic activity and the combination of these agents has a broad coverage of the majority of microorganisms causing infectious complications after TRUBP and may be a valuable future prophylactic regimen. PATIENTS AND METHODS: This was a retrospective cohort study of 2624 men that underwent TRUBP at a Danish university hospital. The patients were divided into three groups. Group 1 (n = 1220) received ciprofloxacin before TRUBP, Group 2 (n = 240) received a combination of pivmecillinam and amoxicillin/clavulanic acid before TRUBP and Group 3 (n = 1161) received an extended prophylaxis with pivmecillinam and amoxicillin/clavulanic acid before and for 2 days after TRUBP. RESULTS: One hundred and ...
Learn more about Oxytetracycline/Sulfamethizole at Largo Medical Center Trade Names :revision Trade Names : Urobiotic Revision...
Cefditoren pivoxil (brand name Spectracef) helps treat bacterial infections. It works by preventing the growth of bacteria or killing bacteria.
Purpose. We compared the quality and pattern of use of antibiotics to treat urinary tract infection (UTI) between institutionalized and home-dwelling elderly.. Methods. We analyzed the quality of use of UTI antibiotics in Swedish people aged ≥65 years at 30 September 2008 (1,260,843 home-dwelling and 86,721 institutionalized elderly). Data regarding drug use, age and sex were retrieved from the Swedish Prescribed Drug Register and information about type of housing from the Social Services Register. In women, we assessed: (1) the proportion who use quinolones (should be as low as possible); (2) the proportion treated with the recommended drugs (pivmecillinam, nitrofurantoin, or trimethoprim) (proportions should be about 40 %, 40 % and 15-20 %, respectively); In men, we assessed: (1) the proportion who used quinolones or trimethoprim (should be as high as possible).. Results. The 1-day point prevalence for antibiotic use for UTI was 1.6 % among institutionalized and 0.9 % among home-dwelling ...
Veterinary antimicrobial consumption patterns vary considerably across Europe. These differences are not only limited to the total amount consumed, but are also observed with regards to the relative proportion of the various antimicrobial classes used. Currently, most of the data on veterinary antimicrobials are reported at sales level without any information on the consumption by different animal species. This hinders a proper comparison of antimicrobial consumption at the species level between countries. However, it is imperative to improve our understanding on antimicrobial usage patterns at the species level, as well as on the drivers contributing to those differences. This will allow for development of tailored interventions with the lowest possible risk for human health, while ensuring effective treatment of diseased livestock. An important step to attain such an objective is to perform detailed comparisons of the antimicrobial consumption in each species between countries.We compared
UROBIOTIC-250 (Oxytetracycline,Sulfamethizole,Phenazopyridine) drug information & product resources from MPR including dosage information, educational materials, & patient assistance.
Abstract Cefditoren pivoxil (Spectracef®, Meiact®) is a third-generation oral cephalosporin with a broad spectrum of activity against pathogens, including both Gram-positive and -negative bacteria,...
108 medications are known to interact with sulfamethizole. Includes Aspirin Buffered (aluminum hydroxide/aspirin/calcium carbonate/magnesium hydroxide), Aspirin Low Strength (aspirin), Carafate (sucralfate).
30 ml/min (insufficienza renale grave) è sufficiente una singola dose di 200 mg di cefditoren ogni 24 ore. ^ N. Iwai, H. Nakamura; M. Miyazu; Y. Watanabe, [Pharmacokinetic, bacteriological and clinical evaluation of cefditoren pivoxil in pediatrics]., in Jpn J Antibiot, vol. 47, nº 2, Feb 1994, pp. 181-94, PMID 8151911. ^ a b Y. Toyonaga, T. Ishihara; T. Sano; T. Tezuka; H. Nakamura, [Bacteriological, pharmacokinetic and clinical studies of cefditoren pivoxil in the pediatric field]., in Jpn J Antibiot, vol. 46, nº 7, Jul 1993, pp. 604-28, PMID 8371496. ^ R. Fujii, H. Yoshioka; A. Okuno; K. Fujita; K. Murono; S. Maruyama; H. Sakata; K. Iseki; Y. Wagatsuma; N. Fukushima, [Pharmacokinetic and clinical studies of cefditoren pivoxil in the pediatric field. Pediatric Study Group of ME1207]., in Jpn J Antibiot, vol. 46, nº 1, Gen 1993, pp. 95-114, PMID 8455336. ^ JT. Li, F. Hou; H. Lu; TY. Li; H. Li, Phase I clinical trial of cefditoren pivoxil (ME 1207): pharmacokinetics in healthy volunteers., ...
ABSTRACT: Cancer treatment should address female-specific survivorship issues, including the hypoestrogenic-related adverse effects of cancer therapies or of natural menopause in survivors. Systemic and vaginal estrogen are widely used for symptomatic relief of vasomotor symptoms, sexual dysfunction, and lower urinary tract infections in the general population. However, given that some types of cancer are hormone sensitive, there are safety concerns about the use of local hormone therapy in women who currently have breast cancer or have a history of breast cancer. Nonhormonal approaches are t... ...
ABSTRACT: Cancer treatment should address female-specific survivorship issues, including the hypoestrogenic-related adverse effects of cancer therapies or of natural menopause in survivors. Systemic and vaginal estrogen are widely used for symptomatic relief of vasomotor symptoms, sexual dysfunction, and lower urinary tract infections in the general population. However, given that some types of cancer are hormone sensitive, there are safety concerns about the use of local hormone therapy in women who currently have breast cancer or have a history of breast cancer. Nonhormonal approaches are t... ...
Urinary tract infections (UTIs) are more prevalent among women than among men (ratio of 20:1), probably secondary to an anatomically short urethra and its close proximity to the vagina and rectum. It is a significant health care problem affecting an estimated 10 % to 20 % of women during their lifetimes and accounting for approximately 5.2 million office visits per year. In the past 30 years, there has been significant development in our understanding of the pathogenesis and management of urinary tract infections. The prevalence of urinary tract infections increases with age. At 1 year, 1 % to 2% of female infants demonstrate bacteriuria. After 1 year of age, the infection decreases to approximately 1 % and remains low until puberty. Between ages 15 to 24, the prevalence of bacteriuria is about 2 % to 3 % and increases to about 15 % at the age 60, 20% after age 65, and 25 % to 50 % after age 80. Sexual activity and pregnancy are major factors in younger age groups, whereas pelvic relaxation, ...
Recurrent urinary tract infections occur in approximately 5% of adult women. It has a significant impact on the affected women's quality of life and on health care costs. It is important to be aware of the physiologically protective factors preventing urinary tract infections. The clinician should also be able to identify relevant risk factors for recurrent infection. Clinical evaluation is relatively straightforward in cases without underlying complicating factors, but urine culture ought to be readily utilised. Treatment should be according to local antibiogram patterns and prophylactic and postcoital preventative strategies can be used according to current evidence. Certain subpopulations such as HIV positive patients require a different approach compared to the general population.
Recurrent urinary tract infections can cause kidney damage if left untreated, especially in kids under age 6. Heres how to recognize the symptom of UTIs and get help for your child.
Recurrent urinary tract infections can cause kidney damage if left untreated, especially in kids under age 6. Heres how to recognize the symptom of UTIs and get help for your child.
Health, ...[EMBARGOED FOR APRIL 15 2011] Urinary tract infections are common in ...In the study young women with a history of recurrent urinary tract in...The results suggest that the probiotic may reduce the rate of recurren...According to study author Ann Stapleton MD of the University of Wash...,Study,examines,new,treatment,for,recurrent,urinary,tract,infections,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
A urologist a few years ago (I had no faith in him at all) asked me about my hygiene, I felt like hitting him!! (Yasmine).. Women expressed quite polarised views towards their doctors. Some describe them as unsupportive and dismissive, often ineffective and at worst unsympathetic and uncaring. my doctors useless as well, he just sais (sic) "its normal for women to get these infections" well what use is that to me (Hilary). Other women describe a lack of care and understanding of the severity of their experience that may be exacerbated by gender differences between patient and practitioner: I had had a bad experience in the past of a GP who refused to prescribe me anything until he (of course it was a man!) had sent off a urine test. This wouldve meant waiting days for the results and I was in agony (Sue).. In some instances doctors were seen as being impractical and patronising:. I only wish the doctor had given me specific tips rather than the try to keep clean nonsense which left ...
Lady with recurrent urinary tract infections was treated at Life Force. She used to experience pricking pain while urinating, burning sensation and offensive urine.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies. ...
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details ...
Posted by Dr Rachel Ng on May 8, 2014 in Womens Health , 12 comments. What is UTI? UTI is when there is presence of significant pathogens (bacteria, yeast) in the urine in the setting of accompanying symptoms of cystitis (bladder infection) or pyelonephritis (kidney infection). UTI can be categorized into lower urinary tract infection which refers to cystitis, which represents the majority of these infections. Upper urinary tract infection refers to kidney infection. What is recurrent UTI? Recurrent UTI is when you get 2 or more infections in 6 months or 3 or more in 1 year. This is still very common in young.... read more ...
In this randomised, double blind trial in women with uncomplicated lower urinary tract infection (UTI), symptomatic treatment with the non-steroidal anti-inflammatory drug (NSAID) diclofenac was inferior to antibiotic treatment with norfloxacin in controlling symptoms. Those treated with diclofenac were 27% less likely to have symptom resolution at day 3 after randomisation and 12% less likely to have symptom resolution at day 7 after randomisation, with higher mean symptom scores, more frequent reconsultations, a higher incidence of clinically diagnosed pyelonephritis, and lower patient satisfaction than those in the norfloxacin group. Conversely, women who received diclofenac were 37% less likely to receive antibiotics until day 30 after randomisation.. A meta-analysis of five trials concluded that antibiotics are clinically superior to placebo in women with uncomplicated lower UTI.18 Our trial, in conjunction with the recently published trial by Gágyor et al,10 suggests that antibiotics are ...
Lorent JA, Arango O, Bielsa O et al. Effect of antibiotic treatment on serum PSA and percent free PSA levels in patients with biochemical criteria for prostatic biopsy and previous lower urinary tract infections. Int J Biol Markers 2002; 17: 84-9 ...
by Julie K. Brown, Miami Herald. Patrick Quercioli was big and burly, and with pumped muscles and an elaborate Indian tattoo on his arm, he looked more like a bodybuilder than a corrections officer.. Though hed been arrested twice - once for allegedly dealing steroids and again, on charges of beating a motorist in a fit of road rage - Quercioli managed to persuade the Florida Department of Corrections to hire him in 2004.. Prisoners say Sgt. Q, as he was known, was among the most menacing officers at Lowell Correctional Institution for women, a man whose patience was not to be tested. But on Sept. 21, 2014, one inmate dared to do just that, after seeing something she wasnt supposed to see: Quercioli allegedly having sex with an inmate in C Dorm, in a rear bathroom behind the officers station.. Disgusted, the inmate - Latandra Ellington - vowed to report it, even though, according to her, Quercioli threatened to kill her if she didnt keep her mouth shut.. Ten days later, after telling her ...

Bupropion (Oral Route) Side Effects - Mayo ClinicBupropion (Oral Route) Side Effects - Mayo Clinic

Amdinocillin * Amdinocillin Pivoxil * Amiloride * Amineptine * Aminophylline * Amitriptyline * Amitriptylinoxide * Amoxapine * ...
more infohttps://www.mayoclinic.org/drugs-supplements/bupropion-oral-route/side-effects/drg-20062478?p=1

Aplenzin Advanced Patient Information - Drugs.comAplenzin Advanced Patient Information - Drugs.com

Amdinocillin. *Amdinocillin Pivoxil. *Amiloride. *Amineptine. *Aminophylline. *Amitriptyline. *Amitriptylinoxide. *Amoxapine. * ...
more infohttps://www.drugs.com/cons/aplenzin.html

Aricept Advanced Patient Information - Drugs.comAricept Advanced Patient Information - Drugs.com

Amdinocillin. *Amdinocillin Pivoxil. *Amineptine. *Aminophylline. *Amiodarone. *Amitriptyline. *Amitriptylinoxide. *Amoxapine. ...
more infohttps://www.drugs.com/cons/aricept.html

Naltrexone And Bupropion (Oral Route) Description and Brand Names - Mayo ClinicNaltrexone And Bupropion (Oral Route) Description and Brand Names - Mayo Clinic

Amdinocillin * Amdinocillin Pivoxil * Amiloride * Amineptine * Aminophylline * Amitriptyline * Amitriptylinoxide * Amoxapine * ...
more infohttps://www.mayoclinic.org/drugs-supplements/naltrexone-and-bupropion-oral-route/description/drg-20122495?p=1

US Patent # 9,566,348. Methods and compositions for the treatment of cancer and infectious
     disease using alpha(2)...US Patent # 9,566,348. Methods and compositions for the treatment of cancer and infectious disease using alpha(2)...

Amdinocillin; Amdinocillin Pivoxil; Amicycline; Amifloxacin; Amifloxacin Mesylate; Amikacin; Amikacin Sulfate; Aminosalicylic ... amdinocillin, amdinocillin pivoxil, amoxicillin, bacampicillin, benzylpenicillinic acid, benzylpenicillin sodium, epicillin., ...
more infohttp://patents.com/us-9566348.html

CA2704853C - Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties 
        - Google...CA2704853C - Immune stimulatory oligoribonucleotide analogs containing modified oligophosphate moieties - Google...

Alamecin; Alexidine; Amdinocillin; Amdinocillin Pivoxil; Amicycline; Amifloxacin; Amifloxacin Mesylate; Amikacin; Amikacin ...
more infohttps://patents.google.com/patent/CA2704853C/en

Antimyasthenic (Oral route, parenteral route)
                            - Loyola University Health SystemAntimyasthenic (Oral route, parenteral route) - Loyola University Health System

Amdinocillin *Amdinocillin Pivoxil *Amineptine *Aminophylline *Amiodarone *Amitriptyline *Amitriptylinoxide *Amoxapine * ...
more infohttp://loyolauniversity.adam.com/content.aspx?productId=47&pid=47&gid=602065

Pivmecillinam for infection - Selexid. Antibiotics, information | Patient - high-kick.ruPivmecillinam for infection - Selexid. Antibiotics, information | Patient - high-kick.ru

Amdinocillin pivoxil (in US); Selexid®. Available as. Tablets. Pivmecillinam is used to treat bacterial infections, such as ...
more infohttp://high-kick.ru/medicine/pivmecillinam-for-infection-selexid

Patente WO2004082525A2 - Sinus delivery of sustained release therapeutics - Google PatentesPatente WO2004082525A2 - Sinus delivery of sustained release therapeutics - Google Patentes

0027] The penicillins that may be used in the biodegradable implants include amdinocillin, amdinocillin pivoxil, amoxicillin, ...
more infohttp://www.google.es/patents/WO2004082525A2?hl=es&cl=en

Patente US7951133 - Sinus delivery of sustained release therapeutics - Google PatentesPatente US7951133 - Sinus delivery of sustained release therapeutics - Google Patentes

The penicillins that may be used in the biodegradable implants include amdinocillin, amdinocillin pivoxil, amoxicillin, ...
more infohttp://www.google.es/patents/US7951133

Pivmecillinam - WikipediaPivmecillinam - Wikipedia

Pivmecillinam (INN) or amdinocillin pivoxil (USAN, trade names Selexid, Penomax and Coactabs) is an orally active prodrug of ... Prodrugs that release pivalic acid when broken down by the body - such as pivmecillinam, pivampicillin and cefditoren pivoxil ... Pham P, Bartlett JG (August 28, 2008). "Amdinocillin (Mecillinam)". Point-of-Care Information Technology ABX Guide. Johns ...
more infohttps://en.wikipedia.org/wiki/Pivmecillinam

US Patent # 7,951,131. Sinus delivery of sustained release therapeutics - Patents.comUS Patent # 7,951,131. Sinus delivery of sustained release therapeutics - Patents.com

The penicillins that may be used in the biodegradable implants include amdinocillin, amdinocillin pivoxil, amoxicillin, ...
more infohttp://patents.com/us-7951131.html

Application # 2005/0002865. Diagnostic/therapeutic agents - Patents.comApplication # 2005/0002865. Diagnostic/therapeutic agents - Patents.com

... amdinocillin, amdinocillin pivoxil, amebucort, amedalin, ametantrone, amezepine, amezinium metilsulfate, amfenac, amfepentorex ... valproate pivoxil, valproic acid, valpromide, valtrate, vancomycin hcl, vaneprim, vanillin, vanitolide, vanyldisulfamide, ... sulbactam pivoxil, sulbenicillin, sulbenox, sulbentine, sulbutiamine, sulclamide, sulconazole, sulfabenz, sulfabenzamide, ...
more infohttp://www.patents.com/us-20050002865.html

US20060008504A1 - Flexible bone composite 
        - Google PatentsUS20060008504A1 - Flexible bone composite - Google Patents

Amdinocillin, Amdinocillin Pivoxil, Amoxicillin, Ampicillin, Apalcillin, Aspoxicillin, Azidocillin, Azlocillin, Bacampicillin, ...
more infohttps://patents.google.com/patent/US20060008504A1/en

List of MeSH codes (D03) - WikipediaList of MeSH codes (D03) - Wikipedia

... amdinocillin MeSH D03.438.260.825.124.036 --- amdinocillin pivoxil MeSH D03.438.260.825.249 --- cyclacillin MeSH D03.438. ... amdinocillin MeSH D03.605.084.737.124.036 --- amdinocillin pivoxil MeSH D03.605.084.737.249 --- cyclacillin MeSH D03.605. ...
more infohttps://en.wikipedia.org/wiki/List_of_MeSH_codes_(D03)

Amebicide | definition of amebicide by Medical dictionaryAmebicide | definition of amebicide by Medical dictionary

amdinocillin. *amdinocillin pivoxil. *amdinopenicillins. *AMDR. *AMDUCA. *AME. *ameba. *-ameba. *amebaism. *amebiasis. * ...
more infohttp://medical-dictionary.thefreedictionary.com/amebicide

Amebas | definition of amebas by Medical dictionaryAmebas | definition of amebas by Medical dictionary

amdinocillin. *amdinocillin pivoxil. *amdinopenicillins. *AMDR. *AMDUCA. *AME. *ameba. *-ameba. *amebaism. *amebas. *amebiasis ...
more infohttp://medical-dictionary.thefreedictionary.com/amebas

METHOD OF MAKING A VACCINE - Patent applicationMETHOD OF MAKING A VACCINE - Patent application

... amdinocillin, amdinocillin pivoxil, amoxicillin, bacampicillin, benzylpenicillinic acid, benzylpenicillin sodium, epicillin, ...
more infohttp://www.patentsencyclopedia.com/app/20110195090

EXPANDABLE DEVICES AND METHODS THEREFOR - Patent applicationEXPANDABLE DEVICES AND METHODS THEREFOR - Patent application

... amdinocillin, amdinocillin pivoxil, amoxicillin, ampicillin, apalcillin, aspoxicillin, azidocillin, azlocillin, bacampicillin, ...
more infohttp://www.patentsencyclopedia.com/app/20110125091

Amdinocillin | Article about amdinocillin by The Free DictionaryAmdinocillin | Article about amdinocillin by The Free Dictionary

Find out information about amdinocillin. any of a group of chemically similar substances obtained from molds of the genus ... Penicillium that were the first antibiotic antibiotic, any of a variety of... Explanation of amdinocillin ... Amdinocillin , Article about amdinocillin by The Free Dictionary https://encyclopedia2.thefreedictionary.com/amdinocillin ... redirected from amdinocillin). Also found in: Dictionary, Thesaurus, Medical. penicillin,. any of a group of chemically similar ...
more infohttp://encyclopedia2.thefreedictionary.com/amdinocillin

AMDT - What does AMDT stand for? The Free DictionaryAMDT - What does AMDT stand for? The Free Dictionary

amdinocillin. *amdinocillin pivoxil. *amdinopenicillins. *AMDIS. *AMDISA. *AMDISS. *AMDIT. *AMDK. *AMDL. *AMDM. *AMDMC ...
more infohttps://acronyms.thefreedictionary.com/AMDT

MabuterolMabuterol

Amdinocillin Pivoxil. Trimethylene Bromide. Antimony Potassium Oxalate. Hydrocotarnine. Agaritine. ©2016 DrugLead US FDA&EMEA. ...
more infohttp://www.druglead.com/cds/mabuterol.html

AMDEC - What does AMDEC stand for? The Free DictionaryAMDEC - What does AMDEC stand for? The Free Dictionary

amdinocillin. *amdinocillin. *amdinocillin. *amdinocillin pivoxil. *amdinopenicillins. *AMDIS. *AMDISA. *AMDISS. *AMDIT. *AMDK ...
more infohttp://acronyms.thefreedictionary.com/AMDEC
  • Prodrugs that release pivalic acid when broken down by the body - such as pivmecillinam, pivampicillin and cefditoren pivoxil - have long been known to deplete levels of carnitine. (wikipedia.org)